Phase II Trial of Subcutaneous Interleukin-2, Subcutaneous Interferon-α, Intravenous Combination Chemotherapy, and Oral Tamoxifen in the Treatment of Metastatic Melanoma: Final Results of Cancer Biotherapy Research Group 94-11

Abstract

This outpatient regimen was associated with significant toxicity including a 7% rate of possible treatment-related death. Tumor regression rates and survival were similar to results reported for chemotherapy alone, or inpatient IL-2-based therapy, but did not suggest an improvement in outcome.